Physician profile
James Hu
NPI 1437277993
$10,592.08
in general payments reported to CMS, 2019-2025
28 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $655 · 2021: $1,425 · 2022: $2,073 · 2023: $2,196 · 2024: $580 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.45 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,192.33 | 2019-2025 | |
| Lilly USA, LLC | $1,139.88 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Janssen Biotech, INC. | $869.17 | 2019-2025 | Tremfya |
| Ucb, INC. | $626.04 | 2019-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $485.62 | 2019-2022 | |
| Amgen INC. | $459.96 | 2019-2025 | Tavneos |
| Genzyme Corporation | $424.98 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $374.26 | 2019-2023 | |
| Pfizer INC. | $346.13 | 2022-2025 | |
| Incyte Corporation | $283.57 | 2022-2023 | Opzelura |
| Astrazeneca Pharmaceuticals Lp | $276.08 | 2024-2025 | Saphnelo |
| Organon LLC | $263.42 | 2024-2025 | Vtama, Hadlima, Renflexis |
| E.R. Squibb & Sons, L.L.C. | $260.92 | 2022-2023 | Sotyktu |
| Stryker Corporation | $250.00 | 2025 | Artix Mt, Clottriever Bold Catheter |
| Leo Pharma INC. | $248.02 | 2022-2025 | Anzupgo, Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.98 | 2019 | |
| Biofrontera INC. | $151.00 | 2019 | |
| Organogenesis INC. | $125.48 | 2023 | Puraply |
| Celgene Corporation | $125.00 | 2019 | |
| Arcutis Biotherapeutics, INC. | $124.99 | 2023 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Tonix Medicines, INC. | $68.05 | 2025 | Tonmya |
| Glaxosmithkline, LLC. | $61.62 | 2025 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $57.15 | 2019-2020 | |
| Octapharma USA, INC. | $56.44 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Sobi, INC | $40.99 | 2024-2025 | |
| Tersera Therapeutics LLC | $25.48 | 2025 | Quzyttir |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.